Skip to content

Circulating Tumor Cells (CTCs) A prognostic biomarker in Patients with Hepatocellular Carcinoma

Circulating Tumor Cells (CTCs) A prognostic biomarker in Patients with Hepatocellular Carcinoma

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
TCTR
Registry ID
TCTR20211226001
Enrollment
70
Registered
2021-12-26
Start date
2019-07-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma Circulating tumor cells, liquid biopsy, hepatocellular carcinoma, biomarker

Interventions

All patients were received standard of treatment by a multidisciplinary team including hepatologists, surgeons, interventionists, and oncologists and were followed for disease progression and overall
Experimental Procedure/Surgery
Standard treatment

Sponsors

None listed

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: The inclusion criteria were newly diagnosed HCC patients with age more than 18 years. The diagnosis of HCC was defined according to American Association of the Study of Liver Diseases guidelines.

Exclusion criteria

Exclusion criteria: The exclusion criteria were patients with previous or concurrent other malignancies.

Design outcomes

Primary

MeasureTime frame
Overall survival 3 years Kaplan-Meier method

Secondary

MeasureTime frame
Factors association with survival 3 years Cox proportional hazard analysis

Countries

Thailand

Contacts

Public ContactThaninee Prasoppokakorn

Chulalongkorn University

thanineeeve@gmail.com66896639930

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026